Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis

Pulmonary Tuberculosis Clinical Trial

Official title:
A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem, Administered Intravenously, Plus Amoxycillin/CA and Faropenem, Administered Orally, Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis.

Status Completed

Clinical Trial Summary

To evaluate the early bactericidal activity (EBA), safety, tolerability and pharmacokinetics of meropenem administered intravenously three times a day, plus amoxycillin/CA administered orally three times a day; and of faropenem administered orally three times a day, plus amoxycillin/CA administered orally three times a day; for 14 consecutive days, in adult participants with newly diagnosed, smear positive pulmonary tuberculosis, in order to help establish proof-of-concept for carbapenem antibiotics as antituberculosis agents and to select the appropriate agent and route of administration for later stage clinical development.

Clinical Trial Description

A single-centre, open-label clinical trial including a total of 45 male or female participants (2 groups of 15 participants receiving an IMP and 1 group of 15 participants receiving Rifafour e-275), aged between 18 and 65 years (inclusive), with newly diagnosed, smear-positive, pulmonary tuberculosis will be enrolled into this trial.

Treatment will be administered for 14 consecutive days in the following dosing schemes:

1. Meropenem 2g intravenously 8-hourly; plus amoxycillin/CA 500mg/125mg orally 8- hourly on days 1-14.

2. Faropenem 600mg orally 8-hourly; plus amoxycillin/CA 500mg/125mg orally 8-hourly on days 1-14.

3. The third arm will receive standard first line TB treatment as per the South African TB guidelines (Rifafour e-275) and is included as a control for the EBA quantitative mycobacteriology and to evaluate whether HRZE gives similar EBA results to that demonstrated in prior studies with this combination. The mycobacteriology laboratory will remain blinded until closure of the EBA results.

Participants will be admitted to the in hospital facility for a period of up to 24 days. During this period they will await their screening results after which they will receive 14 day of IMP. on day 14 intensive PK sampling will be done. They will be discharged on day 15 to the clinic where they will continue on the national TB programme treatment regime. Participants will return to the clinical trial site 14 days after receipt of their last study drug. for a safety evaluation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02349841
Study type	Interventional
Source	Task Foundation NPC
Contact
Status	Completed
Phase	Phase 2
Start date	September 2014
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02736864` - Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae	N/A
Not yet recruiting	`NCT04055441` - A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut University Hospital
Completed	`NCT01927159` - Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers	Phase 1
Active, not recruiting	`NCT01691534` - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)	Phase 2
Completed	`NCT00803322` - Improving Community Based Tuberculosis Care in Ethiopia	Phase 4
Completed	`NCT00834353` - Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis	N/A
Withdrawn	`NCT03277742` - Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz	N/A
Completed	`NCT00057434` - Vitamin A Therapy for Tuberculosis	Phase 3
Recruiting	`NCT06127641` - Rehabilitation of People With Post-tuberculosis Lung Disease	N/A
Recruiting	`NCT06058299` - Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis	Phase 2
Completed	`NCT04550832` - PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)	Phase 2
Completed	`NCT02912832` - Prospective Assessment of TBDx Feasibility	N/A
Completed	`NCT01215851` - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z)	Phase 2
Recruiting	`NCT01503099` - Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease	N/A
Completed	`NCT04608955` - Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081	Phase 2
Recruiting	`NCT05046366` - Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
Completed	`NCT05896930` - Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis	Phase 2
Completed	`NCT02279875` - A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)	Phase 2
Completed	`NCT02554318` - Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia	N/A
Completed	`NCT02053129` - Evaluation of PTB Screening in ANC in Lusaka, Zambia	N/A